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bjectives This study sought to evaluate the prevalence, risk factors, outcomes, and predictors of
ortality of retroperitoneal hematoma (RPH) following percutaneous coronary intervention.
ackground Retroperitoneal hematoma is a serious complication of invasive cardiovascular procedures.
ethods The study sample included 112,340 consecutive patients undergoing percutaneous coro-
ary intervention in a large, multicenter registry between October 2002 and December 2007. End
oints evaluated included the development of RPH and mortality.
esults Retroperitoneal hematoma occurred in 482 (0.4%) patients. Of these, 92.3% were treated
edically and 7.7% underwent surgical repair. Female sex, body surface area 1.8 m2, emergency
rocedure, history of chronic obstructive pulmonary disease, cardiogenic shock, pre-procedural IV
eparin, pre-procedural glycoprotein IIb/IIIa inhibitors, adoption of sheath size 8-F, and use of vascular
losure devices were independent predictors of RPH, whereas the use of bivalirudin was associated with
lower risk. The development of RPH was associated with a higher frequency of post-procedure myocar-
ial infarction (5.81% vs. 1.67%, p  0.0001), infection and/or sepsis (17.43% vs. 3.00%, p  0.0001), and
eart failure (8.00% vs. 1.63%, p  0.0001). In-hospital mortality was signiﬁcantly higher in patients who
eveloped RPH than in patients who did not (6.64% vs. 1.07%, p  0.0001). Among patients with RPH,
ndependent predictors of death were history of myocardial infarction, cardiogenic shock, pre-procedural
reatinine 1.5 mg/dl, and left ventricular ejection fraction 50%.
onclusions Retroperitoneal hematoma is an uncommon complication of contemporary percutane-
us coronary intervention associated with high morbidity and mortality. The identiﬁcation of risk
actors for the development of RPH could lead to modiﬁcation of procedure strategies aimed to-
ard reducing its incidence. (J Am Coll Cardiol Intv 2010;3:845–50) © 2010 by the American
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846he development of complications related to femoral artery
uncture continues to be a frequent occurrence following
ontemporary percutaneous coronary intervention (PCI)
1–4). Whereas the detection and management of compli-
ations confined to below the inguinal ligament, such as
ematoma, false aneurysm, lower extremity ischemia, and
rteriovenous fistula, are usually rapid and with an unevent-
ul course, a retroperitoneal hematoma (RPH) can harbor a
arge volume of blood with minimal external signs, and it is
ssociated with a more serious clinical prognosis (1,3,4). In
atients undergoing PCI, the necessity to take concomitant
ggressive antiplatelet and/or anticoagulation therapy can
urther worsen post-procedural hemorrhage. The impact of
lycoprotein (GP) IIb/IIIa inhibitors and vascular closure
evices (VCDs) on the incidence of RPH has not been fully
tudied (5,6). In addition, predictors of mortality in patients
eveloping RPH are currently unknown. The aim of this
nalysis was to identify the prevalence, risk factors, man-
gement, outcomes, and predictors of mortality of RPH
ollowing PCI.
Methods
Patient population. The study
sample included 112,340 con-
secutive patients undergoing
contemporary PCI in a large,
multicenter, PCI registry be-
tween October 2002 and De-
cember 2007 in Michigan (7,8).
The registry was approved by the
institutional review board of the
University of Michigan and by
ocal institutional review boards. The primary end point was
he development of RPH. Data were prospectively collected
sing standardized definitions and a standardized data
ollection form. Each data form submitted to the coordi-
ating center was assessed for completeness and for face
alidity. All participating centers were audited twice yearly.
random 2% sampling of all cases was selected for audit. In
ddition, all records of patients who died during the same
ospitalization and of patients undergoing coronary artery
ypass surgery were audited. The primary end point was the
evelopment of a RPH, defined as a large hematoma
issecting into the retroperitoneum.
ntithrombotic therapy. All patients received aspirin unless
n allergy was present. Ticlopidine, clopidogrel, GP IIb/IIIa
eceptor inhibitors, and heparin were used at the discretion
f the operator.
tatistical analysis. Continuous variables are expressed as
ean  SD and discrete variables as frequency counts and
ercentages. Continuous variables were evaluated using the
test. Differences between discrete variables were analyzed
bbreviations
nd Acronyms
SA  body surface area
P  glycoprotein
CI  percutaneous
oronary intervention
PH  retroperitoneal
ematoma
CDs  vascular closure
evicessing the chi-square test and, if needed, Fisher exact test. A pvalue 0.05 was considered significant. Logistic regres-
ion models were fitted to determine independent predictors
f RPH and to identify independent predictors of death in
he group of patients who developed RPH. Candidate
ariables were selected on the basis of clinical face value.
tepwise ascending regression was used to identify predic-
ors with a pre-set cutoff p 0.10 for retention of candidate
ariables. Statistical analysis was performed using SAS
ersion 8.2 (SAS Institute, Inc., Cary, North Carolina).
esults
aseline demographics, clinical characteristics, and pre-
rocedural treatments. Among 112,340 patients enrolled in
he registry, RPH occurred in 482 (0.4%). Patients who
eveloped RPH were of similar ages to those who did not.
etroperitoneal hematoma occurred more frequently in
omen (68.1% of patients with RPH vs. 34.1% of patients
ithout RPH, p  0.0001), in patients with a body surface
rea (BSA) 1.8 m2, and in patients with chronic obstruc-
ive pulmonary disease (Table 1). Patients with RPH were
ore likely to have undergone an emergency procedure and
o have received pre-procedural fibrinolytic therapy (p 
.01), GP IIb/IIIa inhibitors, and IV heparin (both p 
.0001) (Table 2). There were no significant differences in
re-procedural use of aspirin or warfarin. We found that
CDs, and in particular Angio-Seal (St. Jude Medical, St.
aul, Minnesota), were more frequently used in patients
ho developed RPH than in those who did not (p 0.0006
or VCDs and p  0.0004 for Angio-Seal) (Table 2). In
ddition, RPH was more frequently detected following
rocedures performed using a sheath size 8-F (Table 2).
n-hospital outcomes. Of the patients who developed RPH,
2.3% were treated medically and 7.7% underwent surgical
epair. The development of RPH was associated with a
igher frequency of post-procedure myocardial infarction
5.81% vs. 1.67%, p  0.0001), infection and/or sepsis
17.43% vs. 3.00%, p  0.0001), and congestive heart
ailure (8.00% vs. 1.63%, p 0.0001) (Table 3). In-hospital
ortality was significantly higher in patients who developed
PH than in those who did not (6.64% vs. 1.07%, p 
.0001). In addition, a nonsignificant trend toward higher
n-hospital mortality was observed in patients with RPH
reated surgically when compared with those treated med-
cally (8.11% vs. 6.52%, p  0.73). Length of in-hospital
tay was significantly higher for patients with RPH than for
atients without (5 days vs. 2 days, p  0.0001) (Table 3).
ultivariable predictors of RPH. Logistic regression analysis
dentified female sex, BSA 1.8 m2, history of chronic
bstructive pulmonary disease, emergency procedure, cardi-
genic shock, use of pre-procedural IV heparin, use of
re-procedural GP IIb/IIIa inhibitors, use of a VCD versus
anual compression, and sheath size 8-F as independentredictors of RPH (Table 4). The use of bivalirudin was
a
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847ssociated with a lower risk for the development of RPH
Table 4). There was good model calibration for the outcome of
PH (Fig. 1) with Hosmer-Lemeshow p  0.63.
ultivariable predictors of in-hospital death. Among those
atients (n  482) who experienced RPH, independent
redictors of death in a sex-controlled model were history of
yocardial infarction, cardiogenic shock, pre-procedural
reatinine level 1.5 mg/dl, and left ventricular ejection
raction 50% (Table 5). The model was well calibrated for
he outcome of death with Hosmer-Lemeshow p  0.17.
iscussion
he prevalence of RPH after contemporary PCI was 0.4%
n this analysis and is the largest experience of RPH
eported in the literature. This finding agrees with previous
iterature (1–4) suggesting that RPH is an uncommon
omplication in patients undergoing PCI. Although RPH
Table 1. Demographic and Historical Differences in Patients With and
Without RPH
Variable
RPH
(n  482)
No RPH
(n  111,858) p Value
Demographic
Age, yrs (SD) 64.3 (13.0) 64.0 (12.3) 0.40
Age 60–69 yrs (%) 26.8 27.0 0.93
Age 70–79 yrs (%) 23.4 24.1 0.74
Age 80 yrs (%) 14.1 11.3 0.06
Female sex (%) 68.1 34.1 0.0001
Current smoking (%) 27.6 26.1 0.45
Body surface area 2.0 m2 (%) 29.3 49.5 0.0001
Body surface area 1.8–1.9 m2 (%) 29.3 29.0 0.90
Body surface area 1.8 m2 (%) 41.4 18.7 0.0001
Lean (BMI 25 kg/m2) (%) 29.7 18.7 0.0001
Overweight (25 BMI 30 kg/m2) (%) 29.7 36.2 0.004
Obese (BMI 30 kg/m2) (%) 40.5 45.1 0.05
Historical (%)
Hypertension 81.1 80.3 0.65
Myocardial infarction 26.8 34.7 0.0002
Diabetes mellitus 29.1 33.9 0.02
Congestive heart failure 12.9 13.3 0.77
Extracardiac vascular disease 25.7 24.1 0.41
Renal failure requiring dialysis 2.9 1.9 0.12
Signiﬁcant valve disease 3.5 4.4 0.34
Gastrointestinal bleeding 2.3 2.2 0.85
Atrial ﬁbrillation 9.8 8.9 0.50
Cardiac arrest 1.0 1.3 0.62
PCI 30.3 42.0 0.0001
CABG 13.5 19.4 0.001
Chronic obstructive pulmonary
disease
23.2 17.6 0.001
BMI body mass index; CABG coronary artery bypass grafting; PCI percutaneous coronary
intervention; RPH retroperitoneal hematoma.an also develop as a subclinical hemorrhage, without tpecific signs such as hypotension, abdominal distension or
ullness, and pain (2,3,9), our findings confirm the associa-
ion between the development of RPH and a significantly
igher risk of morbidity and mortality.
Several risk factors emerged as independent predictors of
PH in our analysis. The adoption of VCDs (vs. manual
ompression) was associated with an increased risk for the
evelopment of RPH. This association was significant for
ngio-Seal (odds ratio [OR]: 1.68, p  0.0001), whereas
here was a nonsignificant trend with Perclose (Abbott
aboratories, Abbott Park, Illinois) (OR: 1.29, p  0.13).
n contemporary practice, arterial access sites are commonly
anaged with percutaneous VCDs, although variable re-
ults as to their benefits and risks have been reported
4–6,10,11). In particular, VCDs, when compared with
anual compression, are associated with a higher incidence
f large pseudoaneurysms not amenable to ultrasound com-
ression, greater blood losses requiring transfusion, a higher
ncidence of arterial stenosis and/or occlusion, and the need
or more extensive surgical repair (12,13). A recent meta-
nalysis on vascular complications associated with the use of
CDs after PCI has suggested that in the setting of PCI,
he rate of complication appeared higher with VasoSeal
Datascope Corporation, Montvale, New Jersey) (6). In our
nalysis, VasoSeal or other VCDs were used only in 0.3%
nd 3.2% of cases, respectively, and were excluded from the
PH prediction model for their statistical inconsistency.
The analysis of different sheath size showed that the use
f catheters 8-F was a predictor of RPH. This data
uggests per se that the use of small catheters is preferable,
egardless the presence of other risk factors for RPH.
The development of RPH has also been associated with
he use of GP IIb/IIIa inhibitors, particularly in conjunction
ith other antithrombotics such as heparin (14–16). Our
nalysis confirms previous reports demonstrating that the
se of both pre-procedural GP IIb/IIIa inhibitors and IV
eparin were independently predictive of the development
f RPH. In addition, similarly to previous experiences (1,5),
emale sex was an independent risk factor for RPH. The
easons for this association remain elusive, although several
ypotheses have been suggested, including differences due
o estrogen-related arterial structures (9,17) and smaller
ommon femoral artery dimensions in women (18). Fur-
hermore, women have different arterial mechanical prop-
rties than men do, such as increased likelihood of arterial
obility (10,19), that may increase the need for multiple
rterial punctures and which, in turn, contribute to in-
reased bleeding risk. We also observed that BSA 1.8 m2
as a risk factor for RPH. Smaller arteries could complicate
PCI and lead to RPH, and not surprisingly, women and
ther patients with a lower BSA are at higher risk.
In addition, our analysis showed that emergency proce-
ures, cardiogenic shock, and the use of antithrombotic
herapy were all independently associated with an increased
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848isk for the development of RPH. It remains to be deter-
ined whether this was due to differences in vascular access
echniques in emergency situations and/or to a more aggres-
Table 2. Presenting, Laboratory, Procedural, Diagnos
Without RPH
Variable
Presenting (%)
Emergency PCI
MI (7 days)
Acute MI (24 h)
Cardiogenic shock
Cardiac arrest
Ventricular tachycardia/ﬁbrillation
Thrombolytics
Laboratory
Baseline pre-creatinine, mg/dl (SD)
Baseline creatinine 1.5 mg/dl (%)
Peak creatinine, mg/dl (SD)
Baseline pre-hemoglobin, g/dl (SD)
Nadir hemoglobin, g/dl (SD)
WHO anemia (%)
Ejection fraction (SD)
Ejection fraction 50%
Total contrast, ml (SD)
Total ﬂuoroscopy time, min (SD)
Procedural (%)
Exceeding MACD*
Angio-Seal VCD
Perclose VCD
Other VCDs
Sheath size 8-F
Sheath size 6-F and 8-F†
Diagnostic (%)
Vessel disease (70%) in 3 or more vessels
3 or more lesions
Intervention in 3 vessels
Thrombus
Calciﬁcation
Treatments (%)
Pre-procedure IV heparin
Pre-procedure LMW heparin
Pre-procedure all GP IIb/IIIa
Pre-procedure ASA
Pre-procedure warfarin
Pre-procedure clopidogrel
Pre-procedure intra-aortic balloon pump
Pre-procedure CPR
Bivalirudin
*Exceeding the maximum allowable contrast dose, which is 5 ml (k
group included 8,413 patients who had a 6.5-F sheath and 989 patien
ASA acetylsalicylic acid; CPR cardiopulmonary resuscitation; GP
contrast dose; MImyocardial infarction; VCD vascular closure devive anticoagulation protocol in these patient subgroups. sThe development of a RPH can lead to severe morbidity
nd increased risk of death. We observed in-hospital mor-
ality of 6.64% in patients who developed a RPH, which was
nd Treatment Differences in Patients With and
H
482)
No RPH
(n  111,858) p Value
5 14.6 0.0001
0 29.7 0.0001
6 16.9 0.0001
5 2.0 0.0001
6 2.3 0.0009
9 1.5 0.49
9 2.2 0.01
1.09) 1.19 (1.08) 0.005
4 11.6 0.39
1.42) 1.26 (1.26) 0.004
1.9) 13.6 (1.9) 0.0001
1.8) 12.3 (2.0) 0.0001
2 28.4 0.07
12.6) 51.5 (11.7) 0.65
0 31.1 0.16
96.9) 208 (90.9) 0.19
12.2) 14.8 (11.4) 0.94
8 7.8 0.02
5 14.8 0.0004
7 8.0 0.59
7 3.2 0.54
2 4.4 0.04
6 37.1 0.04
1 20.4 0.47
6 5.9 0.47
0 0.71 0.40
6 14.2 0.0001
3 18.2 0.95
3 34.0 0.0001
3 6.5 0.47
4 10.9 0.0001
4 94.0 0.56
8 1.9 0.09
7 47.0 0.02
21 0.28 0.77
5 0.9 0.24
39 14.6 0.001
weight)/baseline creatinine (mg/dl). †In addition to 7-F sheaths, this
ad a 7.5-F sheath.
protein; LMW low-molecular-weight;MACDmaximumallowable
er abbreviations as in Table 1.tic, a
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(n 
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849PH (1.07%, p 0.0001). After PCI, the presence of RPH
as associated not only with a higher frequency of post-
rocedure cardiac complications, including myocardial in-
arction and congestive heart failure, but also with a higher
Table 3. In-Hospital Outcomes for Patients With and Without RPH
RPH
(n  482)
No RPH
(n  111,858) p Value
Emergency CABG (%) 1.12 0.43 0.05
All CABG (%) 1.66 1.04 0.18
Gastrointestinal bleeding (%) 13.69 2.68 0.0001
Contrast nephropathy* (%) 13.68 2.68 0.0001
Nephropathy requiring dialysis (%) 1.24 0.27 0.002
Post-procedure transfusion (%) 78.0 4.75 NA
Stroke (%) 1.04 0.37 0.04
Myocardial infarction (%) 5.81 1.67 0.0001
Death (%) 6.64 1.07 0.0001
Revascularization (same lesion site) (%) 0.62 0.57 0.76
MACE (stroke, MI, death, all CABG,
revascularization) (%)
13.49 4.18 0.0001
Infection and/or sepsis (%) 17.43 3.00 0.0001
Congestive heart failure† (%) 8.00 1.63 0.0001
Repeat angiography (%) 7.26 2.32 0.0001
Length of stay (median days) 5 2 0.0001‡
*Patients with renal failure and a history of dialysis excluded. †Patients with congestive heart
failure on admission excluded. ‡The p value is determined by the Wilcoxon rank sum test.
MACEmajor adverse cardiac events (stroke, myocardial infarction, death, all CABG, revascu-
larization); other abbreviations as in Tables 1 and 2.
Table 4. Independent Predictors of RPH
Risk Factors OR 95% CI p Value
Demographic and historical
Female sex 3.44 2.73–4.34 0.0001
BSA 1.8 m2 (referent BSA 2.0 m2) 1.57 1.20–2.05 0.001
1.8 BSA 2.0 m2 (referent BSA 2.0 m2) 1.14 0.88–1.48 0.31
History of chronic obstructive pulmonary
disease
1.32 1.06–1.65 0.01
Procedural
Emergency PCI 1.88 1.48–2.38 0.0001
Cardiogenic shock 1.61 1.08–2.40 0.02
Pre-procedure IV heparin 1.33 1.07–1.64 0.01
Pre-procedure GP IIb/IIIa 2.28 1.81–2.87 0.0001
Bivalirudin 0.51 0.34–0.76 0.001
Angio-Seal device
(referent manual compression)
1.61 1.27–2.06 0.0001
Perclose device
(referent manual compression)
1.24 0.89–1.73 0.21
Sheath size 8-F
(referent sheath size 6-F)
1.53 1.04–2.25 0.03
Sheath size 6-F and 8-F
(referent sheath size 6-F)*
1.02 0.83–1.26 0.83
Model C-statistic 0.75; Hosmer-Lemeshow p value 0.63; deviance p value 1.0. *In addition
to 7-F sheaths, this variable includes 6.5-F sheaths (8,413 patients) and 7.5-F sheaths (989 pa-
tients). Only 0.34% of patients had a sheath size6-F.
BSA body surface area; CI confidence interval; OR odds ratio; other abbreviations as inTables 1 and 3.requency of infection and/or sepsis, gastrointestinal bleed-
ng, and contrast nephropathy.
Of the patients who developed RPH, 92.3% were treated
edically and 7.7% underwent surgical repair. A trend
oward a higher in-hospital mortality was observed in
atients with RPH treated surgically than in those treated
edically, possibly reflective of the fact that a surgical
pproach might be performed in more unstable patients in
hom fluid resuscitation and blood transfusions are inade-
uate in re-establishing a stable hemodynamic status. Im-
ortantly, our analysis of factors associated with mortality
evealed the presence of myocardial infarction, shock, and
enal insufficiency as independent correlates of mortality in
his patient group.
tudy limitations. In view of its observational, nonrandomized
esign, the trend identified toward higher in-hospital mortality
n patients treated surgically does not necessarily support a
anagement strategy actively avoiding surgery for the treat-
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Figure 1. Hosmer-Lemeshow Goodness-of-Fit Test for the Multivariable
Model for the Development of RPH
The x-axis represents number of predicted retroperitoneal hematoma (RPH)
by deciles of risk and the y-axis represents the corresponding observed
number of retroperitoneal hematoma for each decile of risk.
Table 5. Independent Predictors of Mortality in Patients With RPH
Risk Factor OR 95% CI p Value
Female sex 1.67 0.71–3.95 0.24
History of MI 3.99 1.67–9.54 0.002
Cardiogenic shock 7.69 2.68–22.1 0.0002
Pre-procedure creatinine 1.5 mg/dl 2.91 1.17–7.26 0.02
Left ventricular ejection fraction 50% 3.09 1.36–7.06 0.007
Model C-statistic 0.77; Hosmer-Lemeshow p value 0.17; deviance p value 0.51.Abbreviations as in Tables 1, 2, and 4.
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850ent of RPH. In addition, we did not have specific data on the
emoral artery puncture site in patients who developed RPH
nd who underwent surgical management. Thus, we were
nable to further evaluate the relationship between the devel-
pment of RPH and the arterial puncture site. It has been
uggested that femoral arterial access will sometimes be gained
bove the inguinal ligament, where manual compression of the
rtery to stop bleeding is less effective. However, although this
echnique has been advocated as a potential cause of RPH
10,14), adoption of common femoral artery puncture does not
ecessarily avoid the occurrence of RPH (10), given that
revious studies have shown that the site of arterial bleeding is
ften just distal to the inguinal ligament (1–3). In addition, we
ere unable to evaluate other potential predictors of bleeding
uch as peak activated clotting time, or heparin dose, and we
annot exclude that other unknown confounders could have
odified the observed association between risk factors and the
evelopment of RPH.
onclusions
etroperitoneal hematoma is an uncommon complication
f contemporary PCI, and it is associated with high mor-
idity and mortality. Although it remains to be determined,
he identification of risk factors for the development of
PH could lead to modification of procedure strategies
imed toward reducing its incidence, such as, for example,
he adoption of a radial artery approach in high-risk
atients.
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